Skip to main content

UNC Lineberger Comprehensive Cancer Center researchers will share their study findings and expertise at the American Association for Cancer Research’s annual meeting, which is expected to draw thousands to Philadelphia April 18-22 to discuss advances in cancer science.

image2

The meeting will showcase new research on clinical trials, epidemiology, immunology, epigenetics, laboratory science and translational medicine, according to an association news release. More than 18,500 people are expected to attend, including scientists, clinicians and advocates.

Lineberger members will be participating in multiple poster presentation sessions as well as meet-the-expert events. Highlights from the schedule include:

Saturday, April 18

4:30 to 5:30 p.m. Meet-the-Expert session

Lisa Carey – “Triple Negative Breast Cancer: Biologic Advances but a Therapeutic Impasse.” More info

Sunday, April 19

1 to 5 p.m.

Esrta Mutlu DNA adducts induced by in vitro activation of diesel and biodiesel exhaust extracts.” More info

Sreeja Asokan, James E. Bear – “Mena at the nexus of chemotaxis and haptotaxis during tumor progression.” More info

4:05 to 4:25 p.m. Clinical Trials Minisymposium

D. Neil Hayes, Juneko E. Grilley-Olson, David A. Eberhard, Nirali M. Patel, Joel S. Parker, Karen E. Weck, William Y. Kim, Michele C. Hayward, H. Shelton Earp, III, Norman E. Sharpless — “The impact of gene panel sequencing on clinical care in patients with cancer.” More info

Monday, April 20

8 a.m. to noon

Kathleen M. Mulvaney, Jacob Matson, Feng Yan, Dennis Goldfarb, Jeannette Cook, Michael Benjamin Major. UNC Chapel Hill, Chapel Hill, NC – “Elucidating the function of MCM3 ubiquitination by KEAP1: crosstalk between redox-sensing and cell cycle progression.” More info

Amanda L. Rinkenbaugh, Patricia C. Cogswell, Albert S. Baldwin, Jr. — “Inhibition of the IKK/NF-κB pathway impairs glioma stem cell function.” More info

Andy Olshan — “Dietary vitamin A intake and breast cancer risk among African American women: The AMBER Consortium.” More info

Jeanette T. Bensen – “Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African- and European-Americans.” More info

10:40 a.m. to 11

Stephen Hursting – “Obesity and breast cancer: Preclinical perspectives.” More info

11:30 to 11:50 a.m.

Stephen Frye –“Targeting chromatin regulation for cancer therapy: progress towards chemical probes for methyl-lysine readers.” More info

1 to 5 p.m.

Harsha P. Gunawardena, John A. Wrobel, Jonathon O’Brien, Bahjat F. Qaqish, Xian Chen — “Proteogenomic characterization of breast cancer sub-types in patient derived xenografts.” More info

Amanda E.D. Van Swearingen, Marni B. Siegel, Maria J. Sambade, Shivani Sud, Samantha M. Miller, Grace Silva, Ryan E. Bash, Charlene M. Santos, David B. Darr, Brian Golitz, Joel S. Parker, C. Ryan Miller, Gary L. Johnson, Carey K. Anders. — “Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models.” More info

David Darr, Norman Sharpless, Charles Perou, Fernando Pardo-Manuel de Villena, Darla Miller, Katharine Bendt, Stephen D. Hursting. – “Germline genetic variation modulates tumor latency and response to therapy in a mouse model of basal-like breast cancer.” More info

Melissa Troester –Investigation of the relationship between crown-like structures and adipose tissue hormone levels among postmenopausal women with breast cancer.” More info

Aleisha M. Smith, Jessie Xiong, Lucas Hunter, Jamie Jordan, Kelly Clark, David B. Darr, Sharpless Norman, Charles M. Perou, William Y. Kim — “Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors.” More info

Melissa Troester – “Investigation of the relationship between crown-like structures and adipose tissue hormone levels among postmenopausal women with breast cancer.” More info

Cristina M. Contreras, Grace O. Silva, Adam D. Pfefferle, Charles M. Perou – “Targeted agents and chemotherapeutic treatments of genetically engineered Basal-like breast cancer mouse model.” More info

Jeanette T. Bensen—“Gene-based analysis of the fibroblast growth factor receptor signaling pathway identifies an association of the FGF1 gene with risk of estrogen receptor-negative breast cancer: The AMBER consortium.” More info

2:25 to 2:45 Major Symposium

Gary L. Johnson – “Resiliency of the kinome to targeted kinase inhibitors: Strategies to block rewiring.” More info

Tuesday, April 21

8 a.m. to noon

Katherine Hoadley, William Y. Kim – “Progress in The Cancer Genome Atlas bladder cancer project.” More info

Richard A. Moffitt, Katherine Hoadley — “Comprehensive Pan-Genomic characterization of adrenocortical carcinoma.” More info

T.S. Karim Gilbert, Lee M. Graves –“The use of kinome profiling to determine potential resistance pathways in pancreatic cancer cells treated with PIM kinase inhibitors. ” More info

1 to 5 p.m.

Vonn Walter, Michael Catalano, Xiaoying Yin, Patrick Kimes, Xiaobei Xiao Xiao, D. Neil Hayes – “Integrative analysis of miRNAs classify two distinct stages of epithelial cell differentiation in head and neck squamous cell carcinoma (HNSCC).” More info

Amber McCoy, Santosh Dulal, Temitope O. Keku — “Association of FUT2 gene variant, gut bacteria and colorectal adenomas.” More info

David Darr, Lucas Hunter — “Novel fatty-acid synthase inhibitor in combination with platinum-based therapy provides increased tumor killing efficacy in luminal breast murine model.” More info

Melissa A. Troester — “Identifying the role of CRYBB2 in breast cancer tumor-tumor and tumor-stromal interactions.” More info

Emily Janeira — “Cyclooxygenase inhibitors as delivery vehicles for histone deacetylase inhibitors.” More info

Melissa A. Troester — “Genome-wide tissue-based microRNA signature in healthy women predicting breast cancer risk.” More info

Xiao S. Chang, Andrew Jacob Madden, Judith Rivera, Charlene Santos, David Darr, Lucas Hunter, William C. Zamboni. – “The effects of microbeam radiation therapy on the pharmacokinetics of PEGylated liposomal doxorubicin in a triple negative breast cancer GEM model.” More info

Wednesday, April 22

7 to 8 a.m. Meet-the-Expert Session

Temitope O. Keku– “The Gut Microbiome and Colorectal Cancer: Who Is There and What Are They Doing?” More info

8 a.m. to noon

Xi Tian, Minh Nguyen, Henry Foote, Kyle T. Wagner, Hanna K. Sanoff, Autumn J. McRee, Benjamin F. Calvo, Joel E. Tepper, Andrew Z. Wang. “Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload.” More info

Darmood Wei, Aubri Charboneau, Ho-yoon Chung, Donastas Sakellariou-Thompson, Brian Davies, Dennis A. Simpson, William K. Kaufmann, Bernard E. Weissman — “Cyclin G2, a novel target of the SNF5/BAF47 tumor suppressor gene.” More info

Vonn Walter, Xiaoying Yin, Wei Sun, Matthew D. Wilkerson, Michele C. Hayward, Ashley H. Salazar, Charles M. Perou, David N. Hayes –“Integrated genomic analysis of chromosome 11 in squamous tumors.” More info

Haydee Lara, Scott T. Magness – “Single-cell RNA-seq analysis of heterogeneous populations within gastroenteropancreatic neuroendocrine tumors: the role of Sox transcription factors.” More info